Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | phosphodiesterase 4D, cAMP-specific | Starlite/ChEMBL | References |
Homo sapiens | phosphodiesterase 4C, cAMP-specific | References | |
Homo sapiens | phosphodiesterase 4B, cAMP-specific | References | |
Homo sapiens | phosphodiesterase 4A, cAMP-specific | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium leprae | PROBABLE CYTIDINE DEAMINASE CDD (CYTIDINE AMINOHYDROLASE) (CYTIDINE NUCLEOSIDE DEAMINASE) | 0.0559 | 1 | 0.5 |
Mycobacterium ulcerans | cytidine deaminase | 0.0559 | 1 | 0.5 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0392 | 0.6577 | 0.6577 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0447 | 0.7689 | 0.7689 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0447 | 0.7689 | 0.7689 |
Onchocerca volvulus | 0.0559 | 1 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0447 | 0.7689 | 1 |
Trypanosoma brucei | cytidine deaminase | 0.0559 | 1 | 0.5 |
Leishmania major | cytidine deaminase-like protein | 0.0559 | 1 | 0.5 |
Toxoplasma gondii | cytidine and deoxycytidylate deaminase zinc-binding region domain-containing protein | 0.0559 | 1 | 1 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0392 | 0.6577 | 0.6577 |
Trichomonas vaginalis | cytidine deaminase, putative | 0.0559 | 1 | 0.5 |
Entamoeba histolytica | cytidine deaminase, putative | 0.0559 | 1 | 0.5 |
Loa Loa (eye worm) | cyclic AMP specific phosphodiesterase PDE4D5A | 0.0392 | 0.6577 | 0.8553 |
Trichomonas vaginalis | cytidine deaminase, putative | 0.0559 | 1 | 0.5 |
Echinococcus granulosus | cytidine deaminase | 0.0559 | 1 | 1 |
Trypanosoma cruzi | cytidine deaminase-like protein | 0.0559 | 1 | 0.5 |
Trypanosoma cruzi | cytidine deaminase-like protein, putative | 0.0559 | 1 | 0.5 |
Echinococcus multilocularis | cAMP specific 3',5' cyclic phosphodiesterase | 0.0447 | 0.7689 | 0.7689 |
Schistosoma mansoni | camp-specific 35-cyclic phosphodiesterase | 0.0447 | 0.7689 | 1 |
Mycobacterium tuberculosis | Probable cytidine deaminase Cdd (cytidine aminohydrolase) (cytidine nucleoside deaminase) | 0.0559 | 1 | 0.5 |
Giardia lamblia | Cytidine deaminase | 0.0559 | 1 | 1 |
Echinococcus granulosus | cAMP specific 3'5' cyclic phosphodiesterase | 0.0447 | 0.7689 | 0.7689 |
Brugia malayi | Probable 3',5'-cyclic phosphodiesterase R153.1, putative | 0.0392 | 0.6577 | 0.6577 |
Echinococcus multilocularis | cytidine deaminase | 0.0559 | 1 | 1 |
Onchocerca volvulus | 0.0559 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 0 nM | Inhibition of tumor necrosis factor-alpha release from activated human monocyte cells (No data) | ChEMBL. | 9873449 |
IC50 (functional) | 0 nM | Inhibition of tumor necrosis factor-alpha release from activated human monocyte cells in the presence of RP73401 (No data) | ChEMBL. | 9873449 |
IC50 (binding) | = 80 nM | Inhibitory activity against Phosphodiesterase type IV (PDE4) obtained from guinea-pig macrophage was evaluated | ChEMBL. | 9873449 |
IC50 (binding) | = 80 nM | Inhibitory activity against Phosphodiesterase type IV (PDE4) obtained from guinea-pig macrophage was evaluated | ChEMBL. | 9873449 |
Inhibition (functional) | % | Inhibition of LPS-induced tumor necrosis factor-alpha (TNF-alpha) production in mice at 50 mg/kg (No data) | ChEMBL. | 9873449 |
Inhibition (functional) | 0 % | Inhibition of LPS-induced tumor necrosis factor-alpha (TNF-alpha) production in mice at 50 mg/kg (No data) | ChEMBL. | 9873449 |
Ki (binding) | = 54 nM | Binding affinity against PDE4 was determined using [3H]- rolipram in guinea pig brain membrane binding assay | ChEMBL. | 9873449 |
Ki (binding) | = 54 nM | Binding affinity against PDE4 was determined using [3H]- rolipram in guinea pig brain membrane binding assay | ChEMBL. | 9873449 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.